Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect

Core Insights - Caris Life Sciences has announced a partnership with Everlywell to launch Caris Detect, a Multi-Cancer Early Detection (MCED) blood-based screening assay utilizing whole genome sequencing (WGS) technology [1][2][3] Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI technologies [4][5] - Everlywell is a digital health company that combines AI technology with human insight to provide personalized health answers, having delivered nearly 1 billion health insights and transformed care for 60 million people [6] Partnership Details - The partnership aims to enhance access to Caris Detect testing, which is designed to identify multiple cancer types at early stages, ultimately supporting better patient outcomes [3] - Caris expects to launch the Caris Detect assay in the first half of 2026, leveraging Everlywell's consumer-focused platform and established infrastructure [3]